SavedAdd your journal

Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 3

Intravitreal pegaptanib sodium treatment in the type 2a idiopathic juxtafoveolar telangiectasis

Tip 2a idiopatik jukstafoveolar retinal telenjektazi’de intravitreal pegabtanip sodium tedavisi

NECİP KARA
Çiğdem ALTAN
Ahmet Taylan YAZICI
Deniz OYGAR
Hülya GÜNGEL
Pages
243–246
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

One year later, the subretinal fluid was not seen on OCT in the right eye.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 53-year old woman presented with visual deterioration and metamorphopsia.
📊
Key Findings & Data:The dilated fundus examination demonstrated subretinal fluid in the right eye.
💡
Conclusion & Impact:One year later, the subretinal fluid was not seen on OCT in the right eye.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 53-year old woman presented with visual deterioration and metamorphopsia. The dilated fundus examination demonstrated subretinal fluid in the right eye. The Idiopathic Juxtafoveolar Retinal Telangiectasis type 2A was diagnosed based on the optical coherence tomography and the fluorescein angiography. The patient was intravitreally treated using pegaptanib. One year later, the subretinal fluid was not seen on OCT in the right eye.

Özet

Elli üç yaşında bayan hasta görmede azalma ve metomorfopsi şikayetiyle başvurdu. Dilate fundus muyenesinde sağ gözde subretinal sıvı izlendi. Optik Koherans Tomografi (OKT) ve Floresein anjiografi (FA) bulgularına da dayanılarak tip 2a idiopatik jukstafoveal retinal telenjektazi tanısı kondu. Hastanın sağ gözüne intravitreal pegaptanib tedavisi uygulandı. Tedaviden 1 yıl sonraki kontrolde OKT de subretinal sıvı görülmedi.

🔖

Cite This Article

KARA, N., ALTAN, Ç., YAZICI, A. T., OYGAR, D., GÜNGEL, H. (2010). Intravitreal pegaptanib sodium treatment in the type 2a idiopathic juxtafoveolar telangiectasis. Retina-Vitreus, Cilt: 18 - Sayı: 3, 243–246. https://ajindex.com/articles/305158

References (14)

  1. Rodrigo J, Costa RA, Carlucci D, et al.: Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2006;245:1045-1048
  2. Charbel PI, Helb HM, Holz FG, et al.: Correlation of Macular Function with Retinal Thickness is Nonproliferative Type 2 Idiopathic Macular Telangiectasia. Am J ophthalmol. 2008;145:169-175
  3. Sanchez JG, Garcia RA, Wu L, Berrocal MH, et al.: Optical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasis. Retina 2007;27:1214-1220
  4. Cohen SM, Cohen ML, El-Jabali F, et al.: Optical coherence tomography findings in nonproliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina. 2007;27:59-66
  5. Gass JD, Blodi BA.: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993;100:1536-1546
  6. Paunescu LA, Ko TH, Duker JS, et al.: Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113:48-57
  7. Charbel Issa P, Holz FG, Scholl HP.: Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology. 2007;114:1736-1742
  8. Yannuzzi LA, Bardal AM, Freund KB, et al.: Idiopathic Macular Telangiectasia. Arch Ophthalmol. 2006;124:450-460
  9. Watzke RC, Klein ML, Folk JC, et al.: Long-term juxtafoveal retinal telangiectasia. Retina. 2005;25:727-735
  10. Mandal S, Venkatesh P, Abbas Z, et al.: Intravitreal bevacizumab (avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telengiectasia. Graefes Arch Clin Exp Ophthalmol. 2007;245:1825-1829
  11. Vianna RN, Squeri G, Turquetti R, et al.: Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. Can J Ophthalmol. 2008;43:492-493
  12. Potter MJ, Szabo SM, Chan EY, et al.: Photodynamic therapy of subretinal neovascular membrane in type 2A idiopaathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol. 2002;133:149-151
  13. Rishi P, Rishi E, Shroff D.: Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia. Indian J Ophthalmol. 2009;57:241-242
  14. Alldredge CD, Garretson BR.: Intravitreal triamcinalone for the treatment